SAM
Sectoral Asset Management Portfolio holdings
AUM
$162M
1-Year Est. Return
44.84%
1 Year Est. Return
+44.84%
AUM
$162M
AUM Growth
+$10.6M
(+7%)
Holding
98
Top Buys
| 1 | +$5.4M | |
| 2 | +$4.77M | |
| 3 | +$3.41M | |
| 4 |
AnaptysBio
ANAB
|
+$3.39M |
| 5 |
Immatics
IMTX
|
+$1.94M |
Top Sells
| 1 | +$28.6M | |
| 2 | +$13.2M | |
| 3 | +$4.05M | |
| 4 |
PVLA
Palvella Therapeutics
PVLA
|
+$2.92M |
| 5 |
Replimune Group
REPL
|
+$2.15M |
Sector Composition
| 1 | Healthcare | 97.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONC
26
BeOne Medicines Ltd
ONC
$37.4B
| $2.45M | 1.51% |
7,201
-515
|
|
||
27
Abbott
ABT
$212B
| $2.3M | 1.42% |
17,198
+2,000
|
|
||
28
Regeneron Pharmaceuticals
REGN
$77B
| $2.23M | 1.38% |
3,968
+1,195
|
|
||
29
Gilead Sciences
GILD
$155B
| $2.17M | 1.34% |
19,550
-140
|
|
||
30
Boston Scientific
BSX
$131B
| $2.16M | 1.33% |
22,126
+1,000
|
|
||
31
Danaher
DHR
$167B
| $2.1M | 1.3% |
10,575
|
|
||
32
Pfizer
PFE
$146B
| $1.97M | 1.21% |
77,150
|
|
||
33
Insmed
INSM
$34.4B
| $1.93M | 1.19% |
13,425
-1,455
|
|
||
34
Thermo Fisher Scientific
TMO
$232B
| $1.89M | 1.17% |
3,900
|
|
||
35
uniQure
QURE
$1.42B
| $1.79M | 1.11% |
30,740
-24,710
|
|
||
36
BioNTech
BNTX
$27.4B
| $1.74M | 1.08% |
17,660
+1,500
|
|
||
37
Stryker
SYK
$139B
| $1.59M | 0.98% |
4,300
+400
|
|
||
38
Summit Therapeutics
SMMT
$12.7B
| $1.53M | 0.94% |
74,070
+8,850
|
|
||
39
Alnylam Pharmaceuticals
ALNY
$47.5B
| $1.49M | 0.92% |
3,273
-50
|
|
||
40
AstraZeneca
AZN
$293B
| $1.44M | 0.89% |
18,750
+110
|
|
||
41
DexCom
DXCM
$27.1B
| $1.39M | 0.86% |
20,700
+7,500
|
|
||
42
Merck
MRK
$270B
| $1.39M | 0.86% |
16,400
-4,500
|
|
||
43
BioMarin Pharmaceuticals
BMRN
$10.5B
| $1.36M | 0.84% |
25,030
+1,500
|
|
||
|
RAPP
44
Rapport Therapeutics
RAPP
$1.28B
| $1.29M | 0.8% |
43,480
-136,380
|
|
||
45
Mineralys Therapeutics
MLYS
$2.59B
| $1.28M | 0.79% |
33,885
-348,530
|
|
||
46
Syndax Pharmaceuticals
SNDX
$1.78B
| $1.22M | 0.75% |
79,430
+16,130
|
|
||
47
Edwards Lifesciences
EW
$48.9B
| $1.17M | 0.72% |
15,000
|
|
||
48
Tarsus Pharmaceuticals
TARS
$3.02B
| $1.09M | 0.68% |
18,405
-130
|
|
||
|
MRUS
49
DELISTED
Merus
MRUS
| $1.09M | 0.67% |
11,545
-4,130
|
|
||
50
Trevi Therapeutics
TRVI
$1.34B
| $969K | 0.6% |
105,950
-28,200
|
|